JPRN-UMIN000027431
Completed
N/A
The effect of empagliflozin on diuresis and neurohumoral factors in the patients with decompensated heart failure and diabetes mellitus: pilot study - EmpaHF-P
Department of Cardiology, National Hospital Organization Yokohama Medical Center0 sites15 target enrollmentMay 21, 2017
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- decompensated heaat failure type 2 diabetes mellitus
- Sponsor
- Department of Cardiology, National Hospital Organization Yokohama Medical Center
- Enrollment
- 15
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patient who has contraindication for empagliflozin administration 2\. Patient who is in shock at registeration 3\. Patient who is undergone or required intra\-aortic balloon pumping (IABP), percutaneous cardiopulmonary support (PCPS) and/or dialysis at registration 4\. Patient who cannot be obtained informed consent 5\. Patient who is judged as unsuitable for this study by attending physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
Phase 1
Effects of empagliflozin on urine output and renal function in patients with acute heart failureacute decompensated heart failureMedDRA version: 20.0Level: LLTClassification code 10000803Term: Acute heart failureSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2018-003692-35-DEFriedrich Schiller University Jena60
Recruiting
Phase 4
Effect of empagliflozin on renal events in non-diabetic chronic kidney disease patientsChronic kidney disease.Chronic kidney disease (CKD)IRCT20211104052965N1Shahid Beheshti University of Medical Sciences458
Completed
Phase 3
Effects of empagliflozin in diabetes treatmentIRCT20191126045505N1Bojnourd University of Medical Sciences100
Completed
Phase 1
Empagliflozin in non alcoholic fatty liverDiabetic patient with non alcoholic fatty liver.Other specified inflammatory liver diseasesK75.8IRCT20150706023084N18Islamic Azad University30
Recruiting
Phase 4
A study examining the effects of empagliflozin (Jardiance®), a tablet for treatment of diabetes on autonomic nervous system and heart function in patients with type 2 diabetes.Type 2 DiabetesMetabolic and Endocrine - DiabetesCardiovascular - Normal development and function of the cardiovascular systemACTRN12619000887178Baker Heart and Diabetes Institute60